English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and Aims Hyperuricemia is associated with increased vascular events in chronic kidney disease (CKD). Febuxostat is an effective alternative treatment in this subset but there is scarcity of data on its use in patients undergoing dialysis. The aim of our study was to evaluate efficacy and safety profile of febuxostat in hyperuricemic Indian patients on dialysis. Method Fifty four patients with CKD stage 5D and hyperuricemia were included in the study from Jul 2018 to Mar 2019. Febuxostat was started and patients followed-up over 6 months for decline in uric acid and any adverse events. Results Out of 54 cases, 30 were males (55.56%). Mean age was 51.28±16.9 years. Thirty two cases were diabetic (59.26) and all cases were on two or more antihypertensives. Nine cases were suffering from gout at time of inclusion and mean serum creatinine in these cases was 10.47 mg/dl. Symptomatic cases responded to treatment within 2 weeks of therapy. Mean serum uric acid level at 3 months post-treatment (4.65±0.96 mg/dL) was significantly reduced compared from pre-treatment level (8.34± 1.18 mg/dL) [p&amp;lt;0.01]. Serum uric acid level remained significantly low for 6 months without deterioration in eGFR. Blood pressure remained well controlled during therapy period and only four cases required increment of antihypertensive medication. Out of 54 cases, five stopped medication due to adverse events. Out of them, three cases were on peritoneal dialysis. Three cases developed skin rash which subsided once drug was withheld. Most common side effect was nausea (7/54) and headache (6/54). Conclusion Febuxostat at a low dose of 40 mg/dl is well tolerated among dialysis population. It effectively declines serum uric acid level. Gastrointestinal side effects are most common adverse event which corresponds to non-dialysis population. There was no higher risk of skin rash or other major adverse event in this subset. It is also worth mentioning that hyperuricemia is associated with significant vascular events and all cases included in study were hypertensive.

P1597USE OF FEBUXOSTAT IN HYPERURICEMIC PATIENTS UNDERGOING DIALYSIS: TOLERABILITY AND EFFICACY IN INDIAN POPULATION